---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pathophysiology"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pathophysiology. Topics: Substrate overload and lipotoxicity; Insulin resistance and adipose tissue dysfunction; Hepatic de novo lipogenesis and dietary sugars; Hepatocellular injury, inflammation, and macrophage activation; 3 further topics. 7 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Substrate overload and lipotoxicity

> “In defining pathogenic drivers of NAFL and NASH, a useful conceptual framework is that the liver’s capacity to handle the primary metabolic energy substrates, carbohydrates and fatty acids, is overwhelmed, leading to accumulation of toxic lipid species”
> “These metabolites induce hepatocellular stress, injury and death, leading to fibrogenesis and genomic instability that predispose to cirrhosis and hepatocellular carcinoma.”
> “When fatty acids are either supplied in excess or their disposal is impaired, they may serve as substrates for the generation of lipotoxic species that provoke ER stress and hepatocellular injury.”

Source: [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)

> “The presence and severity of NAFL and NASH are substantially determined by factors that govern the supply and disposition of fatty acids, diacylglycerols, ceramides, cholesterol, phospholipids, and other intrahepatic lipids.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.4-2"></a>

### Insulin resistance and adipose tissue dysfunction

> “Insulin resistance is nearly universal in patients with NAFLD and is present in the liver, adipose tissue, and muscle.”
> “Adipose tissue insulin resistance is characterized by increased release of free fatty acids from adipocytes (lipolysis) in the fasting state”
> “A primary disease driver may be an oversupply of fat to adipocytes such that their ability to store triglyceride without inducing cell stress is exceeded, which activates inflammatory pathways and causes insulin resistance.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.4-3"></a>

### Hepatic de novo lipogenesis and dietary sugars

> “The metabolic mechanisms leading to NAFLD reflect an imbalance of energy metabolism in the liver: excess energy, mostly in the form of carbohydrates and fat, entering the liver relative to the ability of the liver to oxidize this energy to CO2 or export it as very-low-density lipoproteins (VLDLs) (Figure 3).”
> “Although excess consumption of any food can lead to development of NAFLD, mono- and disaccharides, especially fructose, sucrose, and high-fructose corn syrup, which is ubiquitous in processed foods, can activate programs of hepatic de novo lipogenesis that further exacerbate NAFLD.”
> “Skeletal muscle insulin resistance, one of the earliest defects associated with metabolic syndrome and prediabetes”

Source: [Loomba et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12168897/)

<a id="topic-2.2.1.4-4"></a>

### Hepatocellular injury, inflammation, and macrophage activation

> “Hepatocellular injury in NASH is characterized by endoplasmic reticulum (ER) stress”
> “likely modulate the hepatocyte’s development of lipotoxic stress, injury and inflammation. The relative contribution of these defects in individuals with NASH is not clarified yet and likely varies among individuals.”

Source: [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)

> “The response of the liver to lipotoxic injury includes activation and recruitment of resident macrophages, which further contributes to hepatocellular injury and stellate cell activation as part of a complex interplay among hepatic cell types.”
> “Additional factors such as hepatocyte uric acid production, exposure to products derived from the gut microbiome, and perhaps low hepatic magnesium levels, may also contribute to the NASH phenotype.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.4-5"></a>

### Fibrogenesis through hepatic stellate cell activation

> “The accumulation of extracellular matrix in the liver, which leads to progressive fibrosis, cirrhosis, portal HTN and liver failure, is the major cause of liver-related death in patients with NAFLD. Fibrogenesis is driven by signaling from stressed or injured hepatocytes and activated macrophages (Kupffer cells in the liver), leading to activation of resident hepatic stellate cells into myofibroblasts to produce matrix proteins faster than they are degraded”
> “Another NASH-specific pathway is through the PNPLA3-I148M variant’s effects directly on stellate cell fibrogenesis”

Source: [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)

<a id="topic-2.2.1.4-6"></a>

### Genetic modifiers of hepatocyte lipid handling

> “Although in some patients, the development and progression of NASH are driven by substrate overload and insulin resistance, in other patients, disease progression is heavily influenced by genetic factors impacting hepatocyte lipid handling.”
> “The I148M polymorphism of PNPLA3 impairs lipolysis of triglyceride in lipid droplets,”
> “Recently, lossof-function variants in HSD17B13, a gene that encodes an enzyme that also localizes to lipid droplets in hepatocytes, have been linked to protection against NASH, progressive fibrosis, and HCC.”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

<a id="topic-2.2.1.4-7"></a>

### PPAR-mediated pathways as therapeutic targets: adipocyte insulin sensitivity, fatty acid oxidation, and inflammation

> “improve adipocyte insulin sensitivity [eg, peroxisome proliferator-activated receptor (PPAR)γ ligands]”

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/)

> “For example, peroxisome proliferator–activated receptor gamma (PPARγ) ligands (for example, pioglitazone), a specialized type of nuclear receptor ligand, enhance adipocyte storage of fat and improve NASH, albeit at the expense of increased peripheral fat stores and weight gain, as shown in clinical trials of these drugs in patients with type 2 diabetes”
> “The PPARα component increases fatty acid oxidation, whereas the PPARδ component has anti-inflammatory effects.”
> “PPARγ ligands (for example, pioglitazone, a member of the family of thiazolidinedione class of drugs) have been studied in several trials and improve steatosis, inflammation and hepatocellular ballooning as well as hepatic fibrosis”

Source: [Friedman et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6553468/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
